|
1
|
Mesa R, Miller CB, Thyne M, Mangan J,
Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG,
et al: Myeloproliferative neoplasms (MPNs) have a significant
impact on patients' overall health and productivity: the MPN
Landmark survey. BMC Cancer. 16:1672016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Björkholm M, Hultcrantz M and Derolf Å:
Leukemic transformation in myeloproliferative neoplasms:
Therapy-related or unrelated? Best Pract Res Clin Haematol.
27:141–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hernández-Boluda JC, Pereira A, Cervantes
F, Alvarez-Larrán A, Collado M, Such E, Arilla MJ, Boqué C, Xicoy
B, Maffioli M, et al: A polymorphism in the XPD gene predisposes to
leukemic transformation and new nonmyeloid malignancies in
essential thrombocythemia and polycythemia vera. Blood.
119:5221–5228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Passamonti F, Rumi E, Pungolino E,
Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L,
Brusamolino E, Pascutto C, et al: Life expectancy and prognostic
factors for survival in patients with polycythemia vera and
essential thrombocythemia. Am J Med. 117:755–761. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wolanskyj AP, Schwager SM, McClure RF,
Larson DR and Tefferi A: Essential thrombocythemia beyond the first
decade: Life expectancy, long-term complication rates, and
prognostic factors. Mayo Clin Proc. 81:159–166. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW: WHO Classification of
Tumours of Haematopioetic and Lymphoid Tissues. Fourth edition.
World Health Organization; Lyon: 2008
|
|
7
|
Rampal R, Ahn J, Abdel-Wahab O, Nahas M,
Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney AS, et
al: Genomic and functional analysis of leukemic transformation of
myeloproliferative neoplasms. Proc Natl Acad Sci USA.
111:E5401–E5410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Delhommeau F, Jeziorowska D, Marzac C and
Casadevall N: Molecular aspects of myeloproliferative neoplasms.
Int J Hematol. 91:165–173. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bolufer P, Barragan E, Collado M, Cervera
J, López JA and Sanz MA: Influence of genetic polymorphisms on the
risk of developing leukemia and on disease progression. Leuk Res.
30:1471–1491. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beer PA, Delhommeau F, LeCouédic JP,
Dawson MA, Chen E, Bareford D, Kusec R, McMullin MF, Harrison CN,
Vannucchi AM, et al: Two routes to leukemic transformation after a
JAK2 mutation-positive myeloproliferative neoplasm. Blood.
115:2891–2900. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hasselbalch HC, Thomassen M, Riley CH,
Kjær L, Larsen TS, Jensen MK, Bjerrum OW, Kruse TA and Skov V:
Whole blood transcriptional profiling reveals deregulation of
oxidative and antioxidative defence genes in myelofibrosis and
related neoplasms. Potential implications of downregulation of Nrf2
for genomic instability and disease progression. PLoS One.
9:e1127862014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kilpivaara O and Levine RL: JAK2 and MPL
mutations in myeloproliferative neoplasms: Discovery and science.
Leukemia. 22:1813–1817. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Santoro C, Sperduti I, Latagliata R,
Baldacci E, Anaclerico B, Avvisati G, Breccia M, Buccisano F,
Cedrone M, Cimino G, et al: Role of treatment on the development of
secondary malignancies in patients with essential thrombocythemia.
Cancer Med. 6:1233–1239. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Andıç N, Ünübol M, Yağcı E, Akay OM,
Yavaşoğlu İ, Kadıköylü VG and Bolaman AZ: Clinical features of 294
turkish patients with chronic myeloproliferative neoplasms. Turk J
Haematol. 33:187–195. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Griesshammer M, Gisslinger H and Mesa R:
Current and future treatment options for polycythemia vera. Ann
Hematol. 94:901–910. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Azevedo AP, Silva SN, De Lima JP, Reichert
A, Lima F, Júnior E and Rueff J: DNA repair genes polymorphisms and
genetic susceptibility to Philadelphia-negative myeloproliferative
neoplasms in a Portuguese population: The role of base excision
repair genes polymorphisms. Oncol Lett. 13:4641–4650. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tefferi A and Pardanani A:
Myeloproliferative neoplasms: A contemporary review. JAMA Oncol.
1:97–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Campregher PV, Santos FP, Perini GF and
Hamerschlak N: Molecular biology of Philadelphia-negative
myeloproliferative neoplasms. Rev Bras Hematol Hemoter. 34:150–155.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tognon R, Nunes Nde S and Castro FA:
Apoptosis deregulation in myeloproliferative neoplasms. Einstein
(Sao Paulo). 11:540–544. 2013.(In English, Portuguese). View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang CQ, Krishnan V, Tay LS, Chin DW, Koh
CP, Chooi JY, Nah GS, Du L, Jacob B, Yamashita N, et al: Disruption
of Runx1 and Runx3 leads to bone marrow failure and leukemia
predisposition due to transcriptional and DNA repair defects. Cell
Rep. 8:767–782. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bănescu C, Trifa AP, Demian S, Lazar
Benedek E, Dima D, Duicu C and Dobreanu M: Polymorphism of XRCC1,
XRCC3, and XPD genes and risk of chronic myeloid leukemia. Biomed
Res Int. 2014:2137902014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nangalia J, Massie CE, Baxter EJ, Nice FL,
Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, et al:
Somatic CALR mutations in myeloproliferative neoplasms with
nonmutated JAK2. N Engl J Med. 369:2391–2405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Levine RL: Mechanisms of mutations in
myeloproliferative neoplasms. Best Pract Res Clin Haematol.
22:489–494. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Batar B, Güven M, Bariş S, Celkan T and
Yildiz I: DNA repair gene XPD and XRCC1 polymorphisms and the risk
of childhood acute lymphoblastic leukemia. Leuk Res. 33:759–763.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baute J and Depicker A: Base excision
repair and its role in maintaining genome stability. Crit Rev
Biochem Mol Biol. 43:239–276. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hoeijmakers JH: Genome maintenance
mechanisms for preventing cancer. Nature. 411:366–374. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Annamaneni S, Gorre M, Kagita S, Addepalli
K, Digumarti RR, Satti V and Battini MR: Association of XRCC1 gene
polymorphisms with chronic myeloid leukemia in the population of
Andhra Pradesh, India. Hematology. 18:163–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zaman S, Wang R and Gandhi V: Targeting
the apoptosis pathway in hematologic malignancies. Leuk Lymphoma.
55:1980–1992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Testa U: Apoptotic mechanisms in the
control of erythropoiesis. Leukemia. 18:1176–1199. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Malherbe JA, Fuller KA, Mirzai B, Kavanagh
S, So CC, Ip HW, Guo BB, Forsyth C, Howman R and Erber WN:
Dysregulation of the intrinsic apoptotic pathway mediates
megakaryocytic hyperplasia in myeloproliferative neoplasms. J Clin
Pathol. Apr 8–2016.(Epub ahead of print). View Article : Google Scholar :
|
|
31
|
Nunes NS, Tognon R, Moura LG, Kashima S,
Covas DT, Santana M, Souto EX, Zanichelli MA, Simões BP, Souza AM
and Castro FA: Differential expression of apoptomiRs in
myeloproliferative neoplasms. Leuk Lymphoma. 54:2047–2051. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tognon R, Gasparotto EP, Neves RP, Nunes
NS, Ferreira AF, Palma PV, Kashima S, Covas DT, Santana M, Souto
EX, et al: Deregulation of apoptosis-related genes is associated
with PRV1 overexpression and JAK2 V617F allele burden in Essential
Thrombocythemia and Myelofibrosis. J Hematol Oncol. 5:22012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tognon R, Nunes NS, Ambrosio L, Souto EX,
Perobelli L, Simões BP, Souza MC, Chauffaille Mde L and de Castro
Attié F: Apoptosis- and cell cycle-related genes methylation
profile in myeloproliferative neoplasms. Leuk Lymphoma.
57:1201–1204. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tognon R, Gasparotto EP, Leroy JM,
Oliveira GL, Neves RP, Carrara Rde C, Kashima S, Covas DT, Santana
M, Souto EX, et al: Differential expression of apoptosis-related
genes from death receptor pathway in chronic myeloproliferative
diseases. J Clin Pathol. 64:75–82. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Olsson M and Zhivotovsky B: Caspases and
cancer. Cell Death Differ. 18:1441–1449. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tefferi A: Myeloproliferative neoplasms: A
decade of discoveries and treatment advances. Am J Hematol.
91:50–58. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rumi E and Cazzola M: Diagnosis, risk
stratification, and response evaluation in classical
myeloproliferative neoplasms. Blood. 129:680–692. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Treliński J, Chojnowski K, Cebula-Obrzut B
and Smolewski P: Impaired apoptosis of megakaryocytes and bone
marrow mononuclear cells in essential thrombocythemia: Correlation
with JAK2V617F mutational status and cytoreductive therapy. Med
Oncol. 29:2388–2395. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tefferi A and Vardiman JW: Classification
and diagnosis of myeloproliferative neoplasms: The 2008 World
Health Organization criteria and point-of-care diagnostic
algorithms. Leukemia. 22:14–22. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Azevedo AP, Silva SN, Reichert A, Lima F,
Júnior E and Rueff J: The role of caspase genes polymorphisms in
genetic susceptibility to philadelphia-negative myeloproliferative
neoplasms in a Portuguese population. Pathol Oncol Res. Mar
14–2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Azevedo AP, Silva SN, Reichert A, Lima F,
Júnior E and Rueff J: Prevalence of the Janus kinase 2 V617F
mutation in Philadelphia-negative myeloproliferative neoplasms in a
Portuguese population. Biomed Rep. 7:370–376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Srour SA, Devesa SS, Morton LM, Check DP,
Curtis RE, Linet MS and Dores GM: Incidence and patient survival of
myeloproliferative neoplasms and myelodysplastic/myeloproliferative
neoplasms in the United States, 2001–2001. Br J Haematol.
174:382–396. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bai J, Xue Y, Ye L, Yao J, Zhou C, Shao Z,
Qian L, Yang R, Li H, Zhang H and Zheng Y: Risk factors of
long-term incidences of thrombosis, myelofibrosis and evolution
into malignance in polycythemia vera: A single center experience
from China. Int J Hematol. 88:530–535. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Passamonti F, Rumi E, Arcaini L, Boveri E,
Elena C, Pietra D, Boggi S, Astori C, Bernasconi P, Varettoni M, et
al: Prognostic factors for thrombosis, myelofibrosis, and leukemia
in essential thrombocythemia: A study of 605 patients.
Haematologica. 93:1645–1651. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gangat N, Wolanskyj AP, McClure RF, Li CY,
Schwager S, Wu W and Tefferi A: Risk stratification for survival
and leukemic transformation in essential thrombocythemia: A single
institutional study of 605 patients. Leukemia. 21:270–276. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tefferi A: Myelofibrosis with myeloid
metaplasia. N Engl J Med. 342:1255–1265. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Barbui T, Finazzi G and Falanga A:
Myeloproliferative neoplasms and thrombosis. Blood. 122:2176–2184.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Riedl SJ and Salvesen GS: The apoptosome:
Signalling platform of cell death. Nat Rev Mol Cell Biol.
8:405–413. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Green DR and Llambi F: Cell death
signaling. Cold Spring Harb Perspect Biol. 7:pii: a006080. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kiraz Y, Adan A, Yandim Kartal M and Baran
Y: Major apoptotic mechanisms and genes involved in apoptosis.
Tumour Biol. 37:8471–8486. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Philchenkov A, Zavelevich M, Kroczak TJ
and Los M: Caspases and cancer: Mechanisms of inactivation and new
treatment modalities. Exp Oncol. 26:82–97. 2004.PubMed/NCBI
|
|
53
|
Ng PW, Porter AG and Jänicke RU: Molecular
cloning and characterization of two novel pro-apoptotic isoforms of
caspase-10. J Biol Chem. 274:10301–10308. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Oliver L and Vallette FM: The role of
caspases in cell death and differentiation. Drug Resist Updat.
8:163–170. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Goldar S, Khaniani MS, Derakhshan SM and
Baradaran B: Molecular mechanisms of apoptosis and roles in cancer
development and treatment. Asian Pac J Cancer Prev. 16:2129–2144.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ding HF, Lin YL, McGill G, Juo P, Zhu H,
Blenis J, Yuan J and Fisher DE: Essential role for caspase-8 in
transcription-independent apoptosis triggered by p53. J Biol Chem.
275:38905–38911. 2000. View Article : Google Scholar : PubMed/NCBI
|
